MIST Logo

Milestone Pharmaceuticals Inc. (MIST) Stock Forecast & Price Prediction

Live MIST Stock Price & Analysis

Home โ€บ Stocks โ€บ Canada | NASDAQ | Healthcare | Biotechnology

$2.27

-0.02 (-0.87%)

12 Month Price Forecast For MIST

$2.27
Current Price
$122.12M
Market Cap
4 Ratings
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to MIST Price Forecasts

+1,001.3%
To High Target of $25.00
+208.4%
To Median Target of $7.00
-11.9%
To Low Target of $2.00

MIST Price Momentum

+5.6%
1 Week Change
+15.8%
1 Month Change
+48.4%
1 Year Change
-3.8%
Year-to-Date Change
-17.5%
From 52W High of $2.75
+102.7%
From 52W Low of $1.12

๐Ÿค” Considering Milestone (MIST)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 16, 2025 5:15 AM UTC

MIST Analyst Ratings & Price Targets

Based on our analysis of 6 Wall Street analysts, MIST has a bullish consensus with a median price target of $7.00 (ranging from $2.00 to $25.00). Currently trading at $2.27, the median forecast implies a 208.4% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,001.3% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

MIST Analyst Consensus

3
Buy
1
Hold
0
Sell

MIST Price Target Range

Low
$2.00
Average
$7.00
High
$25.00
Current: $2.27

Latest MIST Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for MIST.

Date Firm Analyst Rating Change Price Target
Jan 27, 2025 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Oct 14, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Aug 22, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Aug 22, 2024 Rodman & Renshaw Brandon Folkes Buy Initiates $9.00
Jul 1, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
May 30, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
May 16, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Mar 22, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Mar 5, 2024 Piper Sandler Edward Tenthoff Overweight Maintains $5.00
Feb 26, 2024 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Dec 27, 2023 TD Cowen Outperform Maintains $9.00
Aug 14, 2023 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Jun 20, 2023 Jefferies Hold Downgrade $0.00
May 23, 2023 HC Wainwright & Co. Buy Reiterates $0.00
May 15, 2023 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Apr 12, 2023 Oppenheimer Leland Gershell Outperform Maintains $13.00
Mar 30, 2023 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Mar 9, 2023 HC Wainwright & Co. Patrick Trucchio Buy Reiterates $25.00
Nov 14, 2022 HC Wainwright & Co. Patrick Trucchio Buy Maintains $25.00
Apr 22, 2022 Piper Sandler Edward Tenthoff Overweight Upgrade $10.00

Stocks Similar to Milestone Pharmaceuticals Inc.

The following stocks are similar to Milestone based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Milestone Pharmaceuticals Inc. (MIST) Financial Data

Milestone Pharmaceuticals Inc. has a market capitalization of $122.12M with a P/E ratio of -1.6x. The company generates $1.00M in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -5,713.1% and return on equity of -162.9%.

Valuation Metrics

Market Cap $122.12M
Enterprise Value $127.96M
P/E Ratio -1.6x
PEG Ratio -2.6x
Price/Sales 122.1x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin -5,713.1%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +50.8%
Current Ratio 15.4x
Debt/Equity 225.0x
ROE -162.9%
ROA -32.1%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc. (MIST) Company Overview

About Milestone Pharmaceuticals Inc.

What They Do

Develops cardiovascular medicines.

Business Model

Milestone Pharmaceuticals focuses on developing innovative cardiovascular drugs, particularly etripamil, which is currently undergoing clinical trials. The company generates revenue through licensing and collaboration agreements with partners like Ji Xing Pharmaceuticals and research institutions for the development and commercialization of its products.

Additional Information

Founded in 2003 and headquartered in Montrรฉal, Canada, Milestone is targeting significant cardiovascular conditions, which could lead to substantial market opportunities pending successful clinical trial outcomes.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

47

CEO

Mr. Joseph G. Oliveto M.B.A.

Country

Canada

IPO Year

N/A

Milestone Pharmaceuticals Inc. (MIST) Latest News & Analysis

MIST stock latest news image
Quick Summary

Milestone Pharmaceuticals Inc. will host an investor event in New York on February 25, 2025, to discuss its Commercial Launch Plan for cardiovascular medicines.

Why It Matters

Milestone Pharmaceuticals' upcoming investor event may signal strategic developments in its product launch, potentially impacting stock performance and investor sentiment.

Source: GlobeNewsWire
Market Sentiment: Neutral
MIST stock latest news image
Quick Summary

The PDUFA date for CARDAMYSTโ„ข (etripamil) nasal spray, indicated for Paroxysmal Supraventricular Tachycardia (PSVT), is set for March 27, 2025.

Why It Matters

The PDUFA date indicates a critical timeline for regulatory approval, impacting potential revenue and stock performance for the company developing CARDAMYSTโ„ข.

Source: GlobeNewsWire
Market Sentiment: Neutral
MIST stock latest news image
Quick Summary

Milestone Pharmaceuticals granted 113,000 stock options to three new employees under its 2021 Inducement Plan, approved by the Compensation Committee and Board of Directors.

Why It Matters

The granting of equity awards indicates Milestone's commitment to incentivizing talent, which can enhance company performance and drive shareholder value.

Source: GlobeNewsWire
Market Sentiment: Neutral
MIST stock latest news image
Quick Summary

Milestone Pharmaceuticals Inc. (MIST) has shown a technical signal of a "golden cross," with its 50-day moving average surpassing the 200-day moving average, indicating potential investor interest.

Why It Matters

Milestone Pharmaceuticals' golden cross indicates bullish momentum, often signaling potential price increases, attracting technical traders and enhancing investor interest.

Source: Zacks Investment Research
Market Sentiment: Positive
MIST stock latest news image
Quick Summary

The FDA is reviewing the NDA for CARDAMYSTโ„ข for the treatment of PSVT, with a PDUFA date set for March 27, 2025.

Why It Matters

The FDA's review and upcoming decision on CARDAMYSTโ„ข could significantly impact the company's stock price and future revenue, influencing investor sentiment and market positioning.

Source: GlobeNewsWire
Market Sentiment: Neutral
MIST stock latest news image
Quick Summary

Milestone Pharmaceuticals' partner, Ji Xing Pharmaceuticals, reported positive results from a trial in China for etripamil nasal spray in treating paroxysmal supraventricular tachycardia (PSVT).

Why It Matters

Positive trial results for etripamil nasal spray enhance Milestone Pharmaceuticals' market potential, likely boosting investor confidence and interest in the company's stock.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About MIST Stock

What is Milestone Pharmaceuticals Inc.'s (MIST) stock forecast for 2025?

Based on our analysis of 6 Wall Street analysts, Milestone Pharmaceuticals Inc. (MIST) has a median price target of $7.00. The highest price target is $25.00 and the lowest is $2.00.

Is MIST stock a good investment in 2025?

According to current analyst ratings, MIST has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.27. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for MIST stock?

Wall Street analysts predict MIST stock could reach $7.00 in the next 12 months. This represents a 208.4% increase from the current price of $2.27. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Milestone Pharmaceuticals Inc.'s business model?

Milestone Pharmaceuticals focuses on developing innovative cardiovascular drugs, particularly etripamil, which is currently undergoing clinical trials. The company generates revenue through licensing and collaboration agreements with partners like Ji Xing Pharmaceuticals and research institutions for the development and commercialization of its products.

What is the highest forecasted price for MIST Milestone Pharmaceuticals Inc.?

The highest price target for MIST is $25.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,001.3% increase from the current price of $2.27.

What is the lowest forecasted price for MIST Milestone Pharmaceuticals Inc.?

The lowest price target for MIST is $2.00 from at , which represents a -11.9% decrease from the current price of $2.27.

What is the overall MIST consensus from analysts for Milestone Pharmaceuticals Inc.?

The overall analyst consensus for MIST is bullish. Out of 6 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.

How accurate are MIST stock price projections?

Stock price projections, including those for Milestone Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.